Depósito Digital de Documentos de la UAB Encontrados 71 registros  1 - 10siguientefinal  ir al registro: La búsqueda tardó 0.00 segundos. 
1.
16 p, 2.6 MB uPA/uPAR and SERPINE1 in head and neck cancer : Role in tumor resistance, metastasis, prognosis and therapy / Pavón, Miguel Angel (Centro de Investigación Biomédica en Red en Bioingeniería. Biomateriales y Nanomecidicina (CIBER-BBN)) ; Arroyo-Solera, Irene (Centro de Investigación Biomédica en Red en Bioingeniería. Biomateriales y Nanomecidicina (CIBER-BBN)) ; Céspedes, Maria Virtudes (Centro de Investigación Biomédica en Red en Bioingeniería. Biomateriales y Nanomecidicina (CIBER-BBN)) ; Casanova, Isolda (Centro de Investigación Biomédica en Red en Bioingeniería. Biomateriales y Nanomecidicina (CIBER-BBN)) ; León i Vintró, Xavier (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Mangues, Ramón (Centro de Investigación Biomédica en Red en Bioingeniería. Biomateriales y Nanomecidicina (CIBER-BBN)) ; Universitat Autònoma de Barcelona
There is strong evidence supporting the role of the plasminogen activator system in head and neck squamous cell carcinoma (HNSCC), particularly of its uPA (urokinase plasminogen activator)/uPAR (urokinase plasminogen activator receptor) and SERPINE1 components. [...]
2016 - 10.18632/oncotarget.10344
Oncotarget, Vol. 7 Núm. 35 (2016) , p. 57351-57366  
2.
12 p, 804.5 KB RIC versus MAC UCBT in adults with AML : A report from Eurocord, the ALWP and the CTIWP of the EBMT / Baron, Frédéric (University of Liege) ; Ruggeri, Annalisa (Hôpital Saint-Antoine) ; Beohou, Eric (Hospital Saint Antoine) ; Labopin, Myriam (Hospital Saint Antoine) ; Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ; Milpied, Noel (University of Bordeaux) ; Michallet, Mauricette (Centre Hospitalier de Lyon Sud) ; Bacigalupo, Andrea (Ospedale San Martino) ; Blaise, Didier (Aix-Marseille Université) ; Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ; Socié, Gérard (Hospital Saint-Louis) ; Cornelissen, Jan J. (Erasmus Medical Center-Daniel den Hoed Cancer Center) ; Schmid, Christoph (University of Munich) ; Giebel, Sebastian (Gliwice Branch) ; Gorin, Norbert-Claude (Hospital Saint Antoine) ; Esteve, Jordi (Hematology. Hospital Clinic) ; Ciceri, Fabio (Ospedale San Raffaele) ; Savani, Bipin N. (Vanderbilt University Medical Center) ; Mohty, Mohamad (UMRs 938) ; Gluckman, Eliane (Centre Scientifique de Monaco) ; Nagler, Arnon (The Chaim Sheba Medical Center) ; Universitat Autònoma de Barcelona
Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. [...]
2016 - 10.18632/oncotarget.9599
Oncotarget, Vol. 7 Núm. 28 (2016) , p. 43027-43038  
3.
21 p, 9.8 MB Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors / Mira, Alessia (Candiolo Cancer Institute) ; Morello, Virginia (University of Torino Medical School) ; Céspedes, María Virtudes (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ; Perera, Timothy (OCTIMET Oncology Ltd) ; Comoglio, Paolo M. (Candiolo Cancer Institute) ; Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau) ; Michieli, Paolo (University of Torino Medical School) ; Universitat Autònoma de Barcelona
The role of paracrine Hepatocyte Growth Factor (HGF) in the resistance to angiogenesis inhibitors (AIs) is hidden in xenograft models because mouse HGF fails to fully activate human MET. To uncover it, we compared the efficacy of AIs in wild-type and human HGF knock-in SCID mice bearing orthotopic human colorectal tumors. [...]
2017 - 10.18632/oncotarget.16942
Oncotarget, Vol. 8 Núm. 24 (2017) , p. 38193-38213  
4.
8 p, 1.9 MB Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study / Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Jiménez, Amanda (Hospital Clínic i Provincial de Barcelona) ; Vilaplana, Eduard (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ; Montal, Victor (Institut d'Investigació Biomèdica Sant Pau) ; Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ; Pané, Adriana (Hospital Clínic i Provincial de Barcelona) ; Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ; Videla Toro, Laura (Institut d'Investigació Biomèdica Sant Pau) ; Casajoana, Anna (Hospital de Barcelona-SCIAS) ; Clarimón, Jordi (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Ortega, Emilio (Hospital Clínic i Provincial de Barcelona) ; Vidal, Josep (Hospital Clínic i Provincial de Barcelona) ; Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ; Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ; Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Mid-life obesity is an established risk factor for Alzheimer's disease (AD) dementia,whereas late-life obesity has been proposed as a protective state. Weight loss, whichpredates cognitive decline, might explain this obesity paradox on AD risk. [...]
2018 - 10.18632/oncotarget.26162
Oncotarget, Vol. 9 Núm. 78 (january 2018) , p. 34691-34698  
5.
16 p, 1.6 MB Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer : results from the Spanish early access program / Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Palmero, Ramón (Hospital Universitari de Bellvitge) ; Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; Bayona, Cristina (Hospital General Yague (Burgos)) ; Rodríguez-Abreu, Delvys (Hospital Insular de Gran Canaria) ; López-Brea, Marta (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ; Vicente, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Sánchez Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Diz Taín, P (Complejo Asistencial Universitario de León) ; Gordo, Rocío (Roche Farma. S.A.) ; Coca, Margarita (Roche Farma. S.A.) ; de Castro, Javier (Hospital Universitario La Paz (Madrid))
This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive nonsmall-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. [...]
2022 - 10.18632/oncotarget.28244
Oncotarget, Vol. 13 Núm. 1 (2022) , p. 812-827  
6.
14 p, 1.3 MB Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659) / Gordon, Leo I. (Northwestern University Feinberg School of Medicine) ; Karmali, Reem (Northwestern University Feinberg School of Medicine) ; Kaplan, Jason B. (Northwestern University Feinberg School of Medicine) ; Popat, Rakesh (University College London) ; Burris, Howard A. (Sarah Cannon Research Institute/Tennessee Oncology) ; Ferrari, Silvia (Ospedale Papa Giovanni XXIII) ; Madan, Sumit (Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA) ; Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ; Gritti, Giuseppe (Ospedale Papa Giovanni XXIII) ; El-Sharkawi, Dima (Royal Marsden Hospital (Regne Unit)) ; Chau, F. Ian (Royal Marsden Hospital (Regne Unit)) ; Radford, John (University of Manchester) ; de Oteyza, Jaime Pérez (Hospital Universitario HM Sanchinarro (Madrid)) ; Zinzani, Pier Luigi (Università di Bologna) ; Iyer, Swaminathan P. (University of Texas MD Anderson Cancer Center) ; Townsend, William (University College London Hospitals) ; Miao, Harry (Takeda Development Center Americas) ; Proscurshim, Igor (Takeda Development Center Americas) ; Wang, Shining (Takeda Development Center Americas) ; Katyayan, Shilpi (Labcorp Drug Development (Estats Units d'Amèrica)) ; Yuan, Ying (Takeda Development Center Americas) ; Zhu, Jiaxi (Takeda Development Center Americas) ; Stumpo, Kate (Takeda Development Center Americas) ; Shou, Yaping (Takeda Development Center Americas) ; Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ; Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona)
We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). [...]
2023 - 10.18632/oncotarget.28352
Oncotarget, Vol. 14 (january 2023) , p. 57-70  
7.
20 p, 8.2 MB Acute telomere deprotection prevents ongoing BFB cycles and rampant instability in p16 INK4a -deficient epithelial cells / Bernal Martínez, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Moltó Abad, Marc (Hospital Universitari Vall d'Hebron) ; Domínguez, Daniel (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Tusell Padrós, Laura (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Telomere dysfunction drives chromosome instability through endless breakage-fusion-bridge (BFB) cycles that promote the formation of highly rearranged genomes. However, reactivation of telomerase or ALT-pathway is required for genome stabilisation and full malignant transformation. [...]
2018 - 10.18632/oncotarget.25502
Oncotarget, Vol. 9 (june 2018) , p. 27151-27170  
8.
13 p, 2.2 MB Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer / Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mesia, Carles (Institut Català d'Oncologia) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ; Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ; García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ; Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). [...]
2018 - 10.18632/oncotarget.25478
Oncotarget, Vol. 9 (june 2018) , p. 27074-27086  
9.
13 p, 2.1 MB Increased plasma levels of galectin-1 in pancreatic cancer : potential use as biomarker / Martinez-Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques) ; Barranco, Luis E. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Orozco, Carlos A. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Moreno, Mireia (Institut Hospital del Mar d'Investigacions Mèdiques) ; Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ; Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Oldfield, Lucy (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ; Neoptolemos, John P. (Department of General Surgery, University of Heidelberg, Heidelberg, Germany) ; Greenhalf, William (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ; Earl, Julie (Hospital Universitario Ramón y Cajal (Madrid)) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ; Costello, Eithne (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ; Navarro, Pilar (Institut d'Investigació Biomèdica Sant Pau)
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. [...]
2018 - 10.18632/oncotarget.26034
Oncotarget, Vol. 9 (august 2018) , p. 32984-32996  
10.
21 p, 2.1 MB Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants / Cullell, Natalia (Fundació per la Recerca Biomèdica i Social Mútua de Terrassa) ; Carrera, Caty (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Muiño, Elena (Fundació per la Recerca Biomèdica i Social Mútua de Terrassa) ; Torres, Nuria (Fundació per la Recerca Biomèdica i Social Mútua de Terrassa) ; Krupinski, Jerzy (School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom) ; Fernandez-Cadenas, Israel (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular events and recurrence in patients with atrial fibrillation (AF) and cardioembolic stroke. We conducted a literature search to review the current state of OAs pharmacogenomics, focusing on Genome Wide Association Studies (GWAs) in patients treated with vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). [...]
2018 - 10.18632/oncotarget.25579
Oncotarget, Vol. 9 (june 2018) , p. 29238-29258  

Depósito Digital de Documentos de la UAB : Encontrados 71 registros   1 - 10siguientefinal  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.